Pharmacological Profile of VP-343, a Novel Selective Vasopressin V2 Receptor Antagonist, in Rats.

Biological and Pharmaceutical Bulletin - Japan
doi 10.1248/bpb.23.182
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pharmaceutical Society of Japan

Related search

Histopathological Study of Kidney Abnormalities in an Experimental SIADH Rat Model and Its Application to the Evaluation of the Pharmacologic Profile of VP-343, a Selective Vasopressin V2 Receptor Antagonist.

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2001English

Pharmacological Profile of TP-680, a New cholecystokininA Receptor Antagonist

British Journal of Pharmacology
Pharmacology
1996English

Arginine Vasopressin V1a Receptor Antagonist Impairs Maternal Memory in Rats

Physiology and Behavior
PhilosophyBehavioral NeuroscienceExperimentalCognitive Psychology
2008English

The Vasopressin V2 Receptor Antagonists: The Vaptans

Global Journal of Endocrinological Metabolism
2018English

Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure

Circulation
Cardiovascular MedicinePhysiologyCardiology
2001English

A Serine Cluster Prevents Recycling of the V2 Vasopressin Receptor

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1998English

Robalzotan (NAD-299), a Novel Selective 5-Ht 1A Receptor Antagonist

CNS Drug Reviews
2006English

In Vitro Pharmacological Properties of KRH-594, a Novel Angiotensin II Type 1 Receptor Antagonist.

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
1997English

AE9C90CB: A Novel, Bladder-Selective Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder

British Journal of Pharmacology
Pharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy